DAWN (Day One Biopharmaceuticals) Beneish M-Score: -1.78 (As of Jun. 24, 2026)


DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Beneish M-Score?

Day One Biopharmaceuticals DAWN 12 Beneish M-Score is -1.78 as of Jun. 24, 2026. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Day One Biopharmaceuticals ranks worse than 66.67% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Day One Biopharmaceuticals's Beneish M-Score or its related term are showing as below:

DAWN' s Beneish M-Score Range Over the Past 10 Years
Min: -1.78   Med: -1.78   Max: -1.78
Current: -1.78

During the past 7 years, the highest Beneish M-Score of Day One Biopharmaceuticals was -1.78. The lowest was -1.78. And the median was -1.78.


Day One Biopharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Beneish M-Score Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -1.78

Day One Biopharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 16.10 -2.27 -1.78

DAWN vs TYRA, DFTX, MLYS: Beneish M-Score Comparison

For the Biotechnology subindustry, Day One Biopharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Beneish M-Score falls into.


DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Day One Biopharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.5976+0.528 * 1.0769+0.404 * 1.3297+0.892 * 1.206+0.115 * 0.6575
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8661+4.679 * -0.043355-0.327 * 0.9529
=-1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $26.7 Mil.
Revenue was 53.718 + 39.795 + 33.908 + 30.761 = $158.2 Mil.
Gross Profit was 47.637 + 35.315 + 30.143 + 27.877 = $141.0 Mil.
Total Current Assets was $485.1 Mil.
Total Assets was $507.8 Mil.
Property, Plant and Equipment(Net PPE) was $4.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.8 Mil.
Selling, General, & Admin. Expense(SGA) was $120.6 Mil.
Total Current Liabilities was $60.5 Mil.
Long-Term Debt & Capital Lease Obligation was $2.6 Mil.
Net Income was -21.278 + -19.726 + -30.322 + -35.996 = $-107.3 Mil.
Non Operating Income was 4.204 + 4.525 + 4.652 + 5.071 = $18.5 Mil.
Cash Flow from Operations was -14.149 + -5.805 + -24.806 + -58.997 = $-103.8 Mil.
Total Receivables was $13.9 Mil.
Revenue was 29.208 + 93.761 + 8.192 + 0 = $131.2 Mil.
Gross Profit was 26.226 + 92.171 + 7.485 + 0 = $125.9 Mil.
Total Current Assets was $562.3 Mil.
Total Assets was $582.8 Mil.
Property, Plant and Equipment(Net PPE) was $4.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.0 Mil.
Selling, General, & Admin. Expense(SGA) was $115.5 Mil.
Total Current Liabilities was $73.5 Mil.
Long-Term Debt & Capital Lease Obligation was $2.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(26.735 / 158.182) / (13.876 / 131.161)
=0.169014 / 0.105794
=1.5976

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(125.882 / 131.161) / (140.972 / 158.182)
=0.959752 / 0.891201
=1.0769

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (485.099 + 4.478) / 507.827) / (1 - (562.33 + 4.707) / 582.788)
=0.035937 / 0.027027
=1.3297

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=158.182 / 131.161
=1.206

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.029 / (2.029 + 4.707)) / (3.786 / (3.786 + 4.478))
=0.301217 / 0.458132
=0.6575

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(120.587 / 158.182) / (115.45 / 131.161)
=0.762331 / 0.880216
=0.8661

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.619 + 60.522) / 507.827) / ((2.592 + 73.451) / 582.788)
=0.124336 / 0.130481
=0.9529

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-107.322 - 18.452 - -103.757) / 507.827
=-0.043355

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Day One Biopharmaceuticals has a M-score of -1.78 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.78 mean?
Day One Biopharmaceuticals (DAWN) has a Beneish M-Score of -1.78 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Day One Biopharmaceuticals and its competitors. According to the industry distribution chart, Day One Biopharmaceuticals ranks #554 out of 831 companies in the Biotechnology industry, placing it in the top 66.7%.
Is Day One Biopharmaceuticals' Beneish M-Score too high?
Day One Biopharmaceuticals' current Beneish M-Score is -1.78. Based on the distribution chart, Day One Biopharmaceuticals ranks #554 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Beneish M-Score compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #554 out of 831 companies for Beneish M-Score. This places Day One Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Beneish M-Score is -1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Beneish M-Score of -1.78. The current Beneish M-Score is -1.78. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Beneish M-Score is -1.78 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price